Physician profile
Radhika Kotha
NPI 1740418813
$857.29
in general payments reported to CMS, 2019-2025
15 companies · $793 in 2025
The $793 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $49.57 · 2023: $14.94 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $208.06 | 2025 | |
| Novo Nordisk INC | $166.57 | 2023-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $110.95 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.03 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $50.91 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $39.53 | 2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Allergan, INC. | $38.50 | 2020 | |
| Shield Therapeutics INC | $36.68 | 2025 | |
| Lilly USA, LLC | $30.02 | 2025 | Jardiance |
| Dexcom, INC. | $26.19 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $22.83 | 2025 | |
| Merck Sharp & Dohme LLC | $22.24 | 2025 | Capvaxive, Enflonsia, Gardasil 9 |
| Inspire Medical Systems, INC. | $20.38 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.33 | 2025 | Jardiance |
| Indivior INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radhika Kotha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.